Non-coding RNAs (ncRNAs) linked to CLL outcomes: A comprehensive meta-analysis
A recent meta-analysis of 39 studies involving nearly 5000 patients with chronic lymphocytic leukemia (CLL) reveals a consistent correlation between altered expression of various ncRNA classes and poor clinical outcomes. The study, published in BMC Cancer, highlights the potential of ncRNAs as prognostic biomarkers, offering insights into disease trajectories and treatment responses.
The analysis found that dysregulation of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) is associated with shorter overall survival (OS), reduced progression-free survival (PFS), and earlier treatment response times. This is particularly significant given the biological heterogeneity of CLL, where current predictors fall short.
One of the key advantages of ncRNAs as biomarkers is their stability in circulating body fluids, enabling non-invasive, longitudinal monitoring. The authors suggest that changes in ncRNA levels may precede conventional detection methods, allowing for early diagnosis and intervention. This positions ncRNAs as promising candidates for personalized treatment strategies in CLL.
The meta-analysis evaluated 26 studies on miRNAs, 14 studies on lncRNAs, and 7 studies on circRNAs. MiRNA dysregulation showed the strongest correlations with poor OS, PFS, and treatment response. LncRNAs and circRNAs also demonstrated significant associations with adverse outcomes, with circRNAs exhibiting the largest effect sizes.
Among the evaluated miRNAs, miR-29c, miR-34a, miR-181b, and miR-223 showed the most consistent prognostic value. LncRNAs such as Lnc-IRF2-3 and ferroptosis-related lncRNAs, as well as circRNAs like CircLNPEP and CircCAT6A, emerged as highly relevant prognostic markers.
However, the review also noted several methodological limitations that could hinder immediate clinical adoption. These include bias from indirect HR extraction, lack of standardized definitions for outcomes and prognostic factors, and variable reporting of lost-to-follow-up rates and measurement platforms. Despite these challenges, the collective evidence strongly supports a link between dysregulated ncRNA expression and clinically significant differences in survival and disease progression.
The authors emphasize the need for functional studies to elucidate biological mechanisms, improved delivery technologies for ncRNA-directed therapies, and the integration of ncRNA frameworks into clinical trial designs. They believe that these advancements could pave the way for ncRNA-based precision treatments in CLL, ultimately improving patient outcomes.
